At a glance
- Originator Bristol-Myers Squibb
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Cytochrome P-450 enzyme system inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Dermatitis; Psoriasis
Most Recent Events
- 05 Dec 1995 No-Development-Reported for Dermatitis in USA (Topical)
- 05 Dec 1995 No-Development-Reported for Psoriasis in USA (Topical)